Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $62
Travere Therapeutics Inc TVTX
$55.89
▼ -2.43%
($-1.39)
📅 Earnings This Week
Open
$57.29
Prev Close
$57.28
Day Range
$55.30 – $57.55
52W Range
$15.03 – $60.10
Market Cap
$5.20B
Beta
1.02
EPS (TTM)
$-0.27
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2003-07-23 |
| Shares Out. | 92,990,000 |
| Website | travere.com/ ↗ |
| Phone | 18889697879 |
| Employees | 497 |
| Revenue | $127.2M |
| Gross Profit | $125.2M |
| Net Income | -$37.1M |
| Free Cash Flow | $39.2M |
| Total Assets | $555.2M |
| Total Liabilities | $456.5M |
| Equity | $98.7M |
About Travere Therapeutics Inc
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Travere Therapeutics Inc is a publicly traded company under the ticker symbol TVTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
21 analysts (2026-07-01)